Text in german

Antibiotics and cancer

 

 


 

https://pubmed.ncbi.nlm.nih.gov/35514188/ :

A growing link between antibiotics and colon cancer: Independent studies point to an association between antibiotic usage and proximal colon cancer, but a potential mechanism remains elusive:

 

 

 

https://pubmed.ncbi.nlm.nih.gov/36694289/

Introduction: Febrile neutropenia is a common complication experienced by children with cancer or those undergoing hematopoietic stem cell transplantation. Repeated episodes of febrile neutropenia result in cumulative exposure to broad-spectrum antibiotics with potential for a range of serious adverse effects. Short-course antibiotics, even in patients with high-risk febrile neutropenia, may offer a solution.

Areas covered: This review addresses the known broad effects of antibiotics, highlights developments in understanding the relationship between cancer, antibiotics, and the gut microbiome, and discusses emerging evidence regarding long-term adverse antibiotic effects. The authors consider available evidence to guide the duration of empiric antibiotics in pediatric febrile neutropenia and directions for future research.

Expert opinion: Broad-spectrum antibiotics are associated with antimicrobial resistance, Clostridioides difficile infection, invasive candidiasis, significant disturbance of the gut microbiome and may seriously impact outcomes in children with cancer or undergoing allogenic hematopoietic stem cell transplant. Short-course empiric antibiotics are likely safe in most children with febrile neutropenia and present a valuable opportunity to reduce the risks of antibiotic exposure.

 

https://pubmed.ncbi.nlm.nih.gov/36351361/

Our understanding of the gut microbiota has significantly evolved over the last two decades. Advances in the analysis of the gut microbiome continues to reveal complex microbial communities and discoveries about their role in health and diseases, including cancer development, are continuously growing. In addition, research has demonstrated that the use of antibiotics can modulate the gut microbiota composition negatively and influence cancer treatment outcomes, suggesting that antibiotics should be avoided if possible. In this article, we review the role of the gut microbiota in the formation of GI cancers. We show that specific bacterial populations can positively or negatively affect cancer formation with specific attention given to gastric and colorectal cancer. We also review the role of microbial-targeted therapies on cancer treatment outcomes.

 

 

https://pubmed.ncbi.nlm.nih.gov/32968205/

Background: It is understudied whether the posed association of oral antibiotics with colorectal cancer (CRC) varies between antibiotic spectrums, colorectal continuum, and if a non-linear dose-dependent relationship is present.

Design: Three electronic databases and a trial platform were searched for all relevant studies, from inception until February 2020, without restrictions. Random-effects meta-analyses provided pooled effect-sizes (ES) with 95% confidence intervals (CI). Dose-response analyses modelling the relationship between number of days exposed to antibiotics and CRC risk were extended to non-linear multivariable random-effects models.

Results: Of 6483 identified publications ten were eligible, including 4.1 million individuals and over 73,550 CRC cases. The pooled CRC risk was increased among individuals who ever-used antibiotics (ES = 1.17, 95%CI 1.05-1.30), particularly for broad-spectrum antibiotics (ES = 1.70, 95%CI 1.26-2.30), but not for narrow-spectrum antibiotic (ES = 1.11, 95% 0.93-1.32). The dose-response analysis did not provide strong evidence of any particular dose-response association, and the risk patterns were rather similar for colon and rectal cancer.

Discussion: The antibiotic use associated CRC risk seemingly differs between broad- and narrow-spectrum antibiotics, and possibly within the colorectal continuum. It remains unclear whether this association is causal, requiring more mechanistic studies and further clarification of drug-microbiome interactions.

 

 

 



1

Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study.
Zhang J, Haines C, Watson AJM, Hart AR, Platt MJ, Pardoll DM, Cosgrove SE, Gebo KA, Sears CL.Gut. 2019 Nov;68(11):1971-1978. doi: 10.1136/gutjnl-2019-318593. Epub 2019 Aug 19.PMID: 31427405

2
Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus.
Wang JL, Chang CH, Lin JW, Wu LC, Chuang LM, Lai MS.Int J Cancer. 2014 Aug 15;135(4):956-67. doi: 10.1002/ijc.28738. Epub 2014 Mar 21.PMID: 24470385

3
Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer.
Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME, Coebergh JW, Soerjomataram I.Dis Colon Rectum. 2013 Feb;56(2):158-68. doi: 10.1097/DCR.0b013e318279eb30.PMID: 23303143

4

5

The association between colorectal cancer and prior antibiotic prescriptions: case control study.
Armstrong D, Dregan A, Ashworth M, White P, McGee C, de Lusignan S. Br J Cancer. 2020 Mar;122(6):912-917. doi: 10.1038/s41416-019-0701-5. Epub 2020 Jan 13. PMID: 31929515 Free PMC article.


11
Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer.
Jeon JY, Jeong DH, Park MG, Lee JW, Chu SH, Park JH, Lee MK, Sato K, Ligibel JA, Meyerhardt JA, Kim NK. PLoS One. 2013;8(2):e55196. doi: 10.1371/journal.pone.0055196. Epub 2013 Feb 6. PMID: 23405123 Free PMC article.

21
Advanced proximal colon cancer.
Gannon CJ, Malone DL, Royal RE, Schreiber M, Bass BL, Napolitano LM. Surg Endosc. 2002 Mar;16(3):446-9. doi: 10.1007/s00464-001-8304-6. Epub 2001 Nov 16. PMID: 11928025

31
CT colonography in the diagnosis and management of colorectal cancer: emphasis on pre- and post-surgical evaluation.
Hong N, Park SH. World J Gastroenterol. 2014 Feb 28;20(8):2014-22. doi: 10.3748/wjg.v20.i8.2014. PMID: 24587676 Free PMC article. Review.


Inflammation and colon cancer.
Terzić J, Grivennikov S, Karin E, Karin M. Gastroenterology. 2010 Jun;138(6):2101-2114.e5. doi: 10.1053/j.gastro.2010.01.058. PMID: 20420949 Review.
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899. PMID: 28983557 Free PMC article.

61
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG. Ann Intern Med. 2002 Feb 19;136(4):261-9. doi: 10.7326/0003-4819-136-4-200202190-00005. PMID: 11848723
Long-term sedentary work and the risk of subsite-specific colorectal cancer.
Boyle T, Fritschi L, Heyworth J, Bull F. Am J Epidemiol. 2011 May 15;173(10):1183-91. doi: 10.1093/aje/kwq513. Epub 2011 Mar 18. PMID: 21421743

81
Elusive Evidence.
Rhudy LM, Summers D. J Neurosci Nurs. 2023 Oct 1;55(5):149. doi: 10.1097/JNN.0000000000000723. PMID: 37656663 No abstract available.